CAMPTON Biochip-Reader. Picture courtesy of Fraunhofer ISIT

Würth Group participates in second financing round of Campton Diagnostics.

CAMPTON Diagnostics GmbH (“CAMPTON”) was founded to further develop and market biochip-based in vitro diagnostics at the point of care. The technology helps to identify diseases quickly and provide better care for patients. Campton has now been able to win the Würth Group as an investor.

Prof. Reinhold Würth, Chairman of the Supervisory Board of the Würth Group, supports this project and after promising preliminary negotiations, Prof. Würth personally visited CAMPTON Diagnostics GmbH at its location in the Fraunhofer ISIT in Itzehoe.

“I find the business model and the idea behind Campton very convincing,” emphasized Prof. Würth during his visit and gave his consent to the series A financing of the company by the Würth Group. This financing will enable Campton to act for the next few years.

“We are delighted to be working with such a renowned company as Adolf Würth GmbH & Co KG,” said Jürgen Brink, Chief Executive Officer of CAMPTON.

Campton is currently working on the development and certification of the first generations of devices for point-of-care diagnostics, e.g. on-site analysis directly at the patient. In connection with this, Campton scientists develop tests which are to be realized and distributed together with interested partners from the fields of human diagnostics and bioanalytics.

About CAMPTON Diagnostics GmbH

 Campton Diagnostics GmbH was spun off in 2016 by the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe.

Campton developes highly sensitive in-vitro diagnostics for which ISIT manufactures the biochips in the institute’s own clean room. Within a few minutes, the CAMPTON Point-of-Care system allows reliable statements to be made on the indication of infections, cancer or other diseases from a drop of blood. The robust system is portable, easy to operate and therefore very well suited for use independent of location – even directly at the patient’s site. The technology is based on the so-called “electrical biochip technology”.

Disposable cartridges with an integrated biochip are used for the respective measurements. The biochip functions like a conventional ELISA test, but can be read out electrically and is therefore enormously miniaturisable.

The device, the so-called reader, carries out the measurement fully automatically. Nothing more needs to be done except to take the sample with a lancet and insert the cartridge into the device. After a few minutes, the analysis result is shown on the display as a real value.

The CAMPTON platform technology with biochips enables universal use of the device. Only the packaging of the biochip determines which test is involved; the device and large parts of the required reagents remain identical.

More information available at: www.campton-diagnostics.com

About Adolf Würth GmbH & Co. KG

Adolf Würth GmbH & Co KG is a leading specialist in assembly and fastening materials for professional applications. It is the largest individual company of the Würth Group, which operates worldwide. Adolf Würth GmbH & Co KG currently employs over 7,000 people throughout Germany and generated sales of EUR 1.98 billion (including intra-group sales) in the 2018 financial year.

More information available at: www.würth.com

About b.cd GmbH

b.cd GmbH sees itself as a corporate finance consultant for the solution of strategic and financial problems of entrepreneurs in owner-managed, medium-sized family businesses.

b.cd advises clients on mergers & acquisitions (M&A) decisions – acquisition and sale of companies, venture capital and private equity brokerage, joint ventures, mergers and acquisitions as well as debt financing of all kinds.

More information available at: www.brink-cd.de.